First-in-Human OsStic Bone Void Filler

Biomimetic Innovations Limited, an affiliate of PBC Biomed, announced the successful First-in-Human application of its OsStic Injectable Synthetic Bone Void Filler. The procedure, performed on August 7, 2026, by Professor Peter Giannoudis at the University of Leeds Teaching Hospital, involved reconstruction of a lateral tibial plateau fracture. The patient was discharged on the second day post-surgery. This marks the first enrollment in a clinical trial evaluating the safety, performance, and clinical outcomes of OsStic in patients with periarticular fractures. The study is fully funded and sponsored by Biomimetic Innovations Limited. OsStic hardens rapidly, conforms to irregular defect geometries, provides immediate mechanical support, and promotes bone ingrowth and remodeling. This milestone advances next-generation bone fixation technologies and builds the clinical evidence base for OsStic.